Parbendazole
Based on 8 publication(s) in Google Scholar
Parbendazole is a potent inhibitor of microtubule assembly, destabilizes tubulin, with an EC50 of 530 nM, and exhibits a broad-spectrum anthelmintic activity.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 14255-87-9
- Formula: C13H17N3O2
- Molecular Weight:247.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Aging Compound Library
HY-L034
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
Antiparasitic Compound library
HY-L082
-
Targeted Diversity Library
HY-L099
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) Parbendazole
More- EBioMedicine. 2021 Mar:65:103276. [Abstract]
- RSC Adv. 2021 May 25;11(31):18938-18944. [Abstract]
- Commun Biol. 2024 Jan 24;7(1):123. [Abstract]
- Int J Mol Sci. 2023 Jun 30;24(13):10972. [Abstract]
- Molecules. 2026 Mar 5;31(5):864. [Abstract]
- Cancers (Basel). 2022 Nov 28;14(23):5854. [Abstract]
- Indian J Ophthalmol. 2026 Feb 1;74(2):250-258. [Abstract]
- Heinrich-Heine-Universität Düsseldorf. April 2021.
All Parasite Isoforms
More
Biological Activity
EC50: 530 nM (tubulin)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CAL-27 | IC50 |
173 nM
Compound: Parbendazole
|
Antiproliferative activity against human CAL-27 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human CAL-27 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
|
[PMID: 35576703] |
| FaDu | IC50 |
160 nM
Compound: Parbendazole
|
Antiproliferative activity against human FaDu cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human FaDu cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
|
[PMID: 35576703] |
| HFF-1 | IC50 |
>20 μM
Compound: Parbendazole
|
Cytotoxicity against human HFF-1 clls assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human HFF-1 clls assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 35576703] |
| HN-6 | IC50 |
102 nM
Compound: Parbendazole
|
Antiproliferative activity against human HN-6 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HN-6 cells assessed as cell growth inhibition incubated for 72 hrs by CCK-8 assay
|
[PMID: 35576703] |
Parbendazole is a tubulin destabilizer, with an EC50 of 530 nM, and can induce DNA damage[1]. Parbendazole (2-10 μM) inhibits the assembly of microtubules dose-dependently, with an IC50 of 3 μM. Parbendazole (2-20 μM)-treated cells show an complete absence of microtubules in Vero cells[2]. Parbendazole (up to 10 μM) inhibits the growth of CLd-AXE myxamoebae. Parbendazole (2-5 μM) potently inhibits tubulin purified from the wild-type myxamoebae[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 14255-87-9
-
Appearance Solid
-
Molecular Weight 247.29
-
Formula C13H17N3O2
-
Color White to light yellow
-
SMILES
O=C(OC)NC1=NC2=CC=C(CCCC)C=C2N1
-
Synonyms
SKF 29044
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
EBioMedicine
Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. [Abstract]2021 Mar:65:103276. PMID: 33714029 -
RSC Adv
Structural insights into targeting of the colchicine binding site by ELR510444 and parbendazole to achieve rational drug design. [Abstract]2021 May 25;11(31):18938-18944. PMID: 35478655 -
Commun Biol
Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. [Abstract]2024 Jan 24;7(1):123. PMID: 38267545 -
Int J Mol Sci
A Novel Ex Vivo Model to Study Therapeutic Treatments for Myelin Repair following Ischemic Damage. [Abstract]2023 Jun 30;24(13):10972. PMID: 37446147 -
Molecules
2026 Mar 5;31(5):864. PMID: 41828851 -
Cancers (Basel)
Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. [Abstract]2022 Nov 28;14(23):5854. PMID: 36497337 -
Indian J Ophthalmol
Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]2026 Feb 1;74(2):250-258. PMID: 41581041 -
Solvent & Solubility
DMSO : 4 mg/mL (16.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.4 mg/mL (1.62 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.4 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.4 mg/mL (1.62 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.4 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Pure tubulin is obtained from sheep brain by 2 cycles of assembly and disassembly in vitro. Immediately prior to use the protein is centrifuged at 130000 g for 30 min to remove any aggregates. It is used at a protein concentration of 0-2 mg/mL in 0.025 M Pipes buffer, 0-5 mM EGTA, 0-25 mM Mg2SOsup>4, 0.1 mM GTP. Drug binding is determined by equilibrium dialysis using concentrations of parbendazole between 0.1 μM and 4 μM, and 2% (v/v) DMF (dimethyl formamide) as a carrier. Equilibrium is achieved by constant stirring for 2 h at 26°C, bovine serum albumin being used as a standard. 200 μL aliquots are counted in PCS in a 25-200B liquid scintillation counter[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Vero cells, an established cell line derived from monkey kidney are seeded in DMEM supplemented with 10% (v/v) foetal calf serum onto glass coverslips in multiwell dishes. They are allowed to settle, and spread for 2-5 h in a humid atmosphere at 37°C. After this time the medium is changed to DMEM containing 2, 10 or 20 μM parbendazole and 1% (v/v) DMSO controls contained 1 % (v/v) DMSO or had no additions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lo YC, et al. Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential. Sci Rep. 2017 Sep 12;7(1):11261. [Content Brief]
[2]. Havercroft JC, et al. Binding of parbendazole to tubulin and its influence on microtubules in tissue-culture cells as revealed by immunofluorescence microscopy. J Cell Sci. 1981 Jun;49:195-204. [Content Brief]
[3]. Foster KE, et al. A mutant beta-tubulin confers resistance to the action of benzimidazole-carbamate microtubule inhibitors both in vivo and in vitro. Eur J Biochem. 1987 Mar 16;163(3):449-55. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0438 mL | 20.2192 mL | 40.4384 mL | 101.0959 mL |
| 5 mM | 0.8088 mL | 4.0438 mL | 8.0877 mL | 20.2192 mL | |
| 10 mM | 0.4044 mL | 2.0219 mL | 4.0438 mL | 10.1096 mL | |
| 15 mM | 0.2696 mL | 1.3479 mL | 2.6959 mL | 6.7397 mL |
Parbendazole Related Classifications
HY-115364 Related Classifications
Powered by Bioz